Artificial Intelligence

New England Biolabs is launching next-gen sample prep tools, targeting long-read sequencing, RNA bias, and clinical epigenetics to accelerate discovery.

The company launches Artemis, an AI to unify sales tech, and introduces the Forward Deployed AE, a new role to ensure the technology actually works for humans.

Astronaut Chris Hadfield and tech leader Martin Kon to headline Canada's oldest student-run conference, now reaching a global audience for the first time.

Triton's new virtual counter aims to modernize police services, but the move online raises critical questions about security, privacy, and public trust.

Amidst investor panic over AI disrupting commercial real estate, one firm argues the technology is an ally, not a replacement for human brokers.

With its acquisition of Turner Software, Finovifi launches FrontLine Sentry, arming community banks with real-time AI to stop check fraud at the source.

Safe Pro Group's AI-powered edge systems are heading to the U.S. Government, a key validation, yet market reaction raises questions about the deal's size.

GIBO Holdings unveils a next-gen AI engine for mass content production, but a plunging stock price reveals deep market skepticism about its high-stakes plan.

As Canada launches a bold defence strategy, drone-maker Draganfly recruits a former top general to navigate the multi-billion dollar opportunity.

With AI expert Zack Kass headlining, Scale Computing's upcoming summit aims to redefine edge infrastructure, challenging traditional distributed IT models.

With its NAD+ technology featured in Forbes, biotech brand Aramore is challenging marketing hype with scientific rigor and a vision for longevity.

As MARA preps its Q4 earnings call, investors look beyond Bitcoin to see if its ambitious digital energy and AI infrastructure strategy is paying off.

Singapore's Strutt Inc. sees unprecedented demand for its ev¹ Smart Everyday Vehicle. Now, the company faces the ultimate test: scaling up to deliver.

ABLi Therapeutics reports its drug risvodetinib is the first to lower toxic alpha-synuclein levels in a Phase 2 trial, heralding a new era for patients.

With its Felix AI assistant, Syncx is accelerating locums staffing with faster placements and risk assessment to combat a critical healthcare shortage.

Bitdeer leverages complex financial deals to refinance debt and fund a major expansion into the booming AI and high-performance computing market.

Pakistan launches its ambitious national AI strategy, combining a $1B investment with a push for sovereign compute to reshape its economic future.

New research reveals how clinical trial design inflates the placebo effect, offering a key to solving the 90% failure rate for anxiety and depression drugs.

After 65 years, Generac is a finalist for Wisconsin's top manufacturing award, lauded for its tech innovation, economic impact, and community investment.

Latest drill results confirm major expansion at Tesla Zone, as Foran Mining pushes toward a multi-deposit critical minerals camp in Saskatchewan.